Paics Inhibition Is a Potential Therapeutic Strategy for MYC-Positive DLBCL
Sign Up to like & getrecommendations! Published in 2019 at "Blood"
DOI: 10.1182/blood-2019-129613
Abstract: Diffuse large B-cell lymphoma (DLBCL) is among the most common hematological malignancies with varying prognosis. As many as forty percent of patients eventually experience relapsed/refractory disease after combinatorial chemo-immunotherapies, R-CHOP, and prognosis after relapse is… read more here.
Keywords: dlbcl; positive dlbcl; myc positive; myc ... See more keywords